Somewhere around year four or five of consistent treatment, a patient will sit down and say some version of the same sentence: "I don't think it's working like it used to." Sometimes it lasts ten weeks instead of fourteen. Sometimes the forehead softens but the frown lines barely move. Sometimes the result just feels thinner than it used to.
The word that follows is almost always "resistance." And in the overwhelming majority of cases, that word is wrong. True immunologic resistance to botulinum toxin in aesthetic patients is rare — a 2025 narrative review in JMIR Dermatology estimates neutralizing antibody rates in aesthetic use at roughly 0.2% to 0.4%. Meanwhile there is a list of far more common explanations, most of them fixable, and most of them never investigated because everybody jumps straight to the rare one.
This guide works through that list in order of how often it is actually the answer, based on how Carm, BSN, RN approaches the problem at Bellissima BB Med Spa in Frisco, TX.
Before diagnosing anything, it is worth checking that there is a problem at all. Two things routinely masquerade as declining results.
The first is judging too early. Neuromodulators develop over roughly two weeks. Patients who were once thrilled at day fourteen sometimes start checking the mirror at day four, decide it has failed, and never re-evaluate. If you have not looked carefully at day fourteen, you have not actually assessed this round.
The second is a shifting baseline. When you have had smooth glabellar lines for five years, "smooth" stops registering as an achievement and starts registering as normal. The comparison you are running in your head is against last month, not against your untreated face. Photographs taken before your first treatment are unglamorous and extremely useful here.
The single most frequent genuine explanation is scheduling. A patient who booked every twelve weeks for three years starts booking at fourteen, then sixteen, then whenever they notice movement returning. Each round they are treating a muscle that has partially or fully recovered, so the visible "on" period feels shorter — not because the product is weaker, but because they are spending more of the cycle in the fading phase.
There is a second-order effect too. Consistently treated muscles gradually weaken, which is why long-term patients often need slightly fewer units over time. Let the interval stretch far enough and that accumulated benefit unwinds, and the muscle comes back to close to its original strength.
The fix is unglamorous: book the next appointment before you leave the current one, at the interval that worked when you were happy. Our guide to how long Botox actually lasts covers the normal timeline in detail.
Dose is the other big one, and it is uncomfortable because it usually means a previous provider was economizing — sometimes at the patient's own request.
A muscle needs a threshold dose to be meaningfully quieted. Below that threshold you get partial, short-lived softening that reads exactly like "it's not working as well anymore." Patients often arrive at that point gradually: they ask to keep the cost down, the units come down, and the result quietly degrades over several rounds until it feels like a product problem.
Anatomy matters more than most patients expect here. The glabellar complex is a genuinely strong muscle group, and men typically need noticeably more product than women to achieve the same effect in the same area — which is why men's treatments follow different dosing. If you have a strong frown and have been getting a conservative female-average dose, the shortfall is arithmetic, not immunology.
Our breakdown of how many units each area actually needs covers what a properly dosed forehead, glabella and crow's feet treatment looks like.
Two injectors can use identical products and identical unit counts and produce meaningfully different results, because where the product goes matters as much as how much of it there is.
Facial anatomy is not standardized. The frontalis varies in height and width between people. The corrugators sit at different depths. Crow's feet fan out at different angles. Injecting to a template rather than to the face in front of you produces adequate results for people whose anatomy matches the template and disappointing results for everyone else.
Depth is the other variable. Product placed too superficially or too deep for the target muscle does less work than the same product placed correctly. This is invisible to the patient and difficult to diagnose from the outside — which is why a plausible test, when results have declined at one clinic, is to have the same areas treated by a different injector before concluding anything about the molecule.
This is the part of the answer patients almost never hear about, because it happens before the needle reaches the face.
Botulinum toxin arrives as a powder and is reconstituted with saline in the clinic. The dilution used affects how far the product spreads from each injection point. Reconstituted product also has a limited useful life, and the same 2025 review flags improper dilution and prolonged refrigerated storage among the recognized non-immunologic causes of a treatment underperforming. Interbatch variation is on that list too.
You cannot audit this yourself. What you can do is ask — a provider who reconstitutes fresh, uses a consistent dilution, and can explain their protocol without hesitation is telling you something useful about the rest of their practice as well.
Only after the four causes above have been ruled out does true resistance become a reasonable working theory. Here is what it actually is.
Botulinum toxin is a foreign protein. In a small number of people, the immune system eventually produces neutralizing antibodies against it, and once those antibodies are present, the toxin is intercepted before it can act on the muscle. This is called secondary non-response: the treatment worked, and then at some later point stopped.
The distinction matters clinically. Primary non-response — never having responded, even to a first correctly dosed treatment — is a different phenomenon, usually attributed to genetic variation, and it is rarer still.
The recognized risk factors are consistent across the literature, and notably they are mostly about treatment pattern rather than about the person:
Read that list again and notice how much of it is avoidable. The patient most at risk is the one being retreated every eight weeks with generous doses and frequent top-ups — which is to say, the patient whose provider is chasing a perfect result rather than a sustainable one.
Rarely. Against that 0.2% to 0.4% estimated antibody rate in aesthetics, a Korean survey of 673 providers found 53.9% had encountered what they considered resistance — but 59% of those providers put the rate at under 1% of their patients. The gap between how often the word gets used and how often the condition is present is the whole point of this article.
Where formulation does appear to matter is within the group that does stop responding. In the data the review summarizes, among patients with secondary non-response, neutralizing antibodies were found in 32.5% of those treated with onabotulinumtoxinA and 56.7% of those treated with abobotulinumtoxinA — while none of the patients receiving incobotulinumtoxinA developed secondary non-response. That is a limited dataset and should be treated as a signal, not a guarantee.
A handful of ordinary life variables move the needle on duration, and they get blamed on the product far more often than they deserve.
Metabolic rate and training load. Patients who train hard and frequently tend to process neuromodulators somewhat faster and often report duration closer to three months than four. That is not a failure; it is a reason to plan the interval around your body rather than around an average.
A significant change in body weight or fitness. If your metabolism has shifted meaningfully since the last time you were happy with your results, duration can shift with it.
Sun exposure and skin quality. A neuromodulator stops the muscle from folding the skin. It does not repair the skin itself. Years of North Texas sun degrade collagen and elastin, and a line that has become genuinely etched into the skin will not fully erase with muscle relaxation alone — it will soften, and then stop improving. Patients often read that ceiling as declining efficacy when it is really a different problem needing a different tool.
New static lines appearing. Related, and worth naming separately: as skin ages, folds that were purely dynamic start to persist at rest. The treatment is doing exactly what it did last year; the face underneath has changed. Our comparison of Botox versus filler explains where that boundary sits.
There is a simple clinical assessment described in the literature for this exact situation: a unilateral test injection. A measured dose is placed on one side only — typically at the brow — and the two sides are compared at two weeks. If the treated side responds and the untreated side does not, the toxin is reaching the muscle and working, and the problem lies in dose, placement or interval rather than immunology.
It is a cheap, low-risk test, and it converts a vague suspicion into an actual answer. It also protects patients from the far more expensive path of switching products repeatedly, or committing to a year-long break, on the strength of a guess.
When a patient comes to Bellissima BB Med Spa saying their results have declined, the sequence is deliberately boring, because boring is where the answer usually is.
We start with history: which areas, what dose, what product, what interval, how long the result held, and when it changed. Most cases resolve here — a stretched interval, a conservative dose, or a switch of provider lines up neatly with the timing of the decline.
Then Carm assesses the muscles directly, watching you frown, raise your brows and squint, because a muscle that has genuinely been treated consistently for years moves differently from one that has been under-treated. Then we treat properly: correct dose for your anatomy, correct placement, and a three-to-four-month interval with no booster top-ups.
If a correctly dosed, correctly placed treatment at a proper interval still fails to produce an effect at two weeks, then and only then does the conversation turn to formulation and to resistance.
The recognized approaches are straightforward. Switching to a purified, complexing-protein-free formulation is the first step — which is one of the practical arguments for Xeomin, and for Daxxify, which is stabilized with a peptide rather than accessory proteins. For complete non-response, the literature discusses a drug holiday of twelve to eighteen months before resuming with a purified product.
That second option is a significant commitment, which is exactly why it should never be the first thing anyone reaches for. Ruling out interval, dose, placement and handling first is not stalling — it is the diagnosis.
Prevention is genuinely simpler than treatment in this case, and it comes down to four habits:
None of this is exotic. It is simply the difference between a treatment plan and a series of appointments.
Bellissima BB Med Spa is a private injectables studio inside Mattison Avenue Salon Suites on Warren Parkway in Frisco, TX, serving patients across Frisco, Plano, McKinney, Prosper, Allen and North Dallas. Every treatment is performed by Carm, BSN, RN — a licensed registered nurse with more than thirty years of medical experience across emergency medicine, anesthesia recovery and surgical settings — working under physician oversight, and every patient completes a Good Faith Exam before treatment.
If your results have changed and nobody has explained why, that is a conversation worth having properly. Book a consultation and bring whatever history you have. You can also read more about Carm's background before you come in.
You probably are not — estimated neutralizing antibody rates in aesthetic patients are around 0.2% to 0.4%. Genuine resistance is only a reasonable conclusion after a correctly dosed, correctly placed treatment at a proper interval produces no effect at the two-week mark. Before that, interval drift, underdosing, placement and product handling are all far more likely explanations.
The most common reasons are a stretched treatment interval and a dose that has crept downward over several rounds. Both produce exactly the pattern patients describe as "wearing off faster." A less common but real factor is a change of injector, since placement and dilution vary between providers.
It might, but only if formulation is genuinely the problem. Switching products while the real cause is an underdose or a stretched interval just moves the same disappointment to a new label. That said, both are purified of accessory complexing proteins, which is why they are the recognized next step when resistance is actually suspected.
The approach discussed in the literature for complete non-response is a drug holiday of roughly twelve to eighteen months before resuming with a purified formulation. It is a significant commitment and is not something to attempt on a hunch — it belongs at the end of a proper diagnostic process, not the start.
Treating less than three months apart and taking booster injections within about three weeks of a treatment are both identified as significantly increasing the risk of antibody formation. Frequent top-ups in pursuit of a perfect result are, ironically, one of the better ways to end up with no result at all.
Not as a general precaution — routine breaks are not necessary, and letting your interval stretch is more likely to make results feel weaker than stronger. A deliberate long pause is a specific strategy for confirmed complete non-response, not a maintenance habit. If you are considering it, have the conversation with your injector first.
